Intratumoral therapy increases response to checkpoint inhibitor for melanoma

Source: Healio, February 2017

The phase 2 registration trial designed to evaluate ImmunoPulse IL-12 in combination with pembrolizumab for unresectable metastatic melanoma showed an increase in response rates among patients who were not expected to respond to anti–PD-1 therapy alone.

ImmunoPulse IL-12 (OncoSec Medical) is an intratumoral immunotherapy platform that delivers DNA-based interleukin-12.

The single-arm, open-label trial evaluated the combination of ImmunoPulse IL-12 with pembrolizumab (Keytruda, Merck), a PD-1 checkpoint inhibitor, in patients with stage III/IV melanoma who had a low likelihood of responding to an anti–PD-1 therapy based on their tumor biomarkers (CD8–positive tumor infiltrating lymphocytes < 22% PD-1hiCTLA-4+).

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories